Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

Liu, 1998, Constitutive and antibody-induced internalization of prostate-specific membrane antigen, Cancer Res, 58, 4055 Emmett, 2017, Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy, J Med Radiat Sci, 64, 52, 10.1002/jmrs.227 Wright, 1996, Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy, Urology, 48, 326, 10.1016/S0090-4295(96)00184-7 Heck, 2019, Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer, Eur Urol, 75, 920, 10.1016/j.eururo.2018.11.016 Emmett, 2019, Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression, Clin Genitourin Cancer, 17, 15, 10.1016/j.clgc.2018.09.014 Rasul, 2021, Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer, Eur J Nucl Med Mol Imaging, 48, 1650, 10.1007/s00259-020-05082-5 Stenger M. Calculating H-score. The ASCO Post. April 10, 2015. https://ascopost.com/issues/april-10-2015/calculating-h-score/. O, 2016, Practical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0, Radiology, 280, 576, 10.1148/radiol.2016142043 Scher, 2016, Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3, J Clin Oncol, 34, 1402, 10.1200/JCO.2015.64.2702 Paschalis, 2019, Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer, Eur Urol, 76, 469, 10.1016/j.eururo.2019.06.030